Analytical Concordance of PD-L1 Assays Utilizing Antibodies From FDA-Approved Diagnostics in Advanced Cancers: A Systematic Literature Review

PURPOSE: Four programmed death ligand 1 (PD-L1) immunohistochemistry assays (28-8, 22C3, SP263, and SP142) have been approved for use by the US Food and Drug Administration (FDA). Analytical concordance between these assays has been evaluated in multiple studies. This systematic review included stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Prince, Emily A., Sanzari, Jenine K., Pandya, Dimple, Huron, David, Edwards, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202559/
https://www.ncbi.nlm.nih.gov/pubmed/34136742
http://dx.doi.org/10.1200/PO.20.00412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202559/
https://www.ncbi.nlm.nih.gov/pubmed/34136742
http://dx.doi.org/10.1200/PO.20.00412

Ejemplares similares